Tapering antipsychotics with N-acetylcysteine for stable schizophrenia
Treatments studied
Part of Mental health clinical trials.
This study is testing whether adding a supplement called N-acetylcysteine (a type of antioxidant) can help people who are stable on antipsychotic medication safely reduce their medication dose. It aims to see if this approach helps maintain wellness while lowering medication side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with schizophrenia or a related thought disorder.
- Your symptoms (like hallucinations or strange thoughts) have been mild and stable for at least 3 months.
- You have been on the same dose of your antipsychotic medication for at least 3 months.
- You have not been hospitalized for psychiatric reasons in the past 6 months.
- You are not currently pregnant or breastfeeding (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether NAC (a nutrient-like supplement) can reduce symptoms in people who are at high risk for developing psychosis. It may help by testing a safer, non-standard treatment approach for early warning signs.
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
This trial tests whether N-acetylcysteine (a supplement-like medicine) can help people with alcohol use disorder reduce or stop drinking. You may be randomly assigned to receive N-acetylcysteine or a comparison treatment, and you’ll complete interviews during the study.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study looks at whether N-acetylcysteine (NAC), a supplement/medication, can help autism-related symptoms by trying to target brain chemistry. You may be able to join if you previously took part in a related NAC study and can keep your usual medications steady.
This study tests whether N-acetylcysteine (a supplement) can reduce repetitive or self-injurious behaviors in people with Cornelia de Lange syndrome. It involves 4 hospital visits over 18 weeks.
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.